期刊文献+

脂肪酶抑制剂产生菌筛选 被引量:5

Screening of lipase inhibitor producing strain
下载PDF
导出
摘要 为了开发减肥用品的微生物菌种 ,用脂肪酶活性为筛选模型分别以肉汤培养基和马铃薯培养基培养土壤分离获得 1 1个菌株LA、LB、LC、LD、LE、LF、LG、MA、MB、MC和MD ,且同时考察了各菌株发酵液对淀粉酶、蛋白酶的抑制效果 ,结果表明LC、LE、LF、LG、MC和MD对淀粉酶有抑制作用 ,其抑制率分别为3 7%、5 8%、32 %、3 2 %、70 2 %和 73 5 % ;LA、LB、LC、MB对蛋白酶有抑制效果 ,抑制率分别为 55 %、31 2 5 %、37 5 %和 2 7 3 % ;LA、LB、LC、LD、LE、LF、MC和MD对脂肪酶有抑制效果 ,抑制率分别为 79%、54 8%、2 0 9%、1 2 9%、61 3 %、80 6 %、2 4 7%和 35 1 %。菌种LF对脂肪酶有较强的抑制作用 ,对淀粉酶抑制作用较小 ,对蛋白酶没有抑制作用。初步鉴定该菌属于芽孢杆菌属 ,命名为BacillusspLF。 To develop anti obesity products,a screening method using the inhibitory activity of lipase as model was established. Strains LA, LB, LC, LD, LE, LF, LG, MA, MB, MC, MD isolated from soil were cultured. The inhibitory activities of their broth on amylase, protease and lipase were determined. Results showed that LC, LE, LF, LG, MC and MD could inhibit amylase by 3 7%, 5 8%, 32%, 3 2%, 70 2% and 73 5% respectively; LA, LB, LC and MB could inbibit protease by 55%, 31 25%, 37 5% and 27 2% respectively; LA, LB, LC, LD, LE, LF, MC and MD could inhibit lipase by 79%, 54 8%, 20 9%, 12 9%, 61 3%, 80 6%, 24 7% and 35 1% respectively. The results suggest that strain LF showed high lipase inhibitory activity while low amylase inhibitory activity and no protease inhibitory activity. Strain LF is designated as Bacillus sp.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2002年第11期641-642,共2页 Chinese Journal of Antibiotics
基金 浙江工业大学科学研究中心资助项目 ( 2 0 0 10 0 52 )
关键词 脂肪酶抑制剂 产生菌 筛选 肥胖 Inhibitor Amylase Protease Lipase Bacillus sp Screening
  • 相关文献

参考文献5

  • 1Xu C Y Zhuge J.-[J].微生物学报,1999,39(2):185-185.
  • 2Hu H F Zhu B Q.-[J].中国医药工业杂志,1995,26(11):484-484.
  • 3Meng X F Gong B Y 等.-[J].中国抗生素杂志,1997,22(6):401-401.
  • 4Zhang S Z.酶制剂工业[M].-,1984.446,484,660.
  • 5Du R Q.生物统计学[M].-,1985.102.

同被引文献32

  • 1Bernard MY Cheung.Rise and fall of anti-obesity drugs[J].World Journal of Diabetes,2011,2(2):19-23. 被引量:7
  • 2王燕飞,张晖,郭贯新.米胚芽中胰脂肪酶抑制剂的抑制机理研究[J].食品科技,2004,29(6):94-96. 被引量:11
  • 3胡海峰,朱宝泉,龚炳永.微生物来源的胆固醇生物合成酶抑制剂研究:抗生素SIPI-8926-III的研究[J].中国医药工业杂志,1995,26(11):484-486. 被引量:12
  • 4[1]Bray AG.The epidemic of obesity and changes in food intake:the fluoride hypothesis [J].Physiol Behav,2004,81 (1):115-121.
  • 5[2]Chiesi M,Huppertz C,Hofbauer KG.Pharmacotherapy ofobesity:targets and perspectives [J].Trends Pharmacol Sci,2001,22 (5):247-254.
  • 6[3]Gargonuri Y,Ransac S,Verger R.Covalent inhibition of digestive lipase:an in vitro study [J].Biochim Biophys Acta,1997,1344(1):6-37.
  • 7[4]Hatano T,Yamashita A,Hashitomo T,et al.Flavan dimers with lipase inhibitory activity from Cassia nomame [J].Phytochem,1997,46 (5):893-900.
  • 8[5]Ballinger A,Peikin R S.Orlistat:its current status as an antiobesity drug [J].Eur J Pharm,2002,440 (2-3):109-117.
  • 9[6]Umezawa H,Aoyagi T,Hazato T,et al.Esterastin,an in hibitor of esterase,produced by actinomycetes [J].J Antibiot (Tokyo),1978,31 (6):639-641.
  • 10[7]Clapham CJ,Arch JR,Tadayyon M.Anti-obesity drugs:a critical review of current therapies and future opportunities [J].Pharmcol Ther,2001,89(1):81-121.

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部